Baseline demographics and clinical characteristics, HIV‐1 suppression (HIV‐1 RNA <50 copies/mL), HBV suppression (HBV DNA <29 IU/mL), alanine aminotransferase (ALT) normalization (2018 American Association for the Study of Liver Diseases criteria), hepatitis B e antigen (HBeAg) and surface antigen (HBsAg) loss/seroconversion at week 144, and treatment‐emergent adverse events (TEAEs) through to end of study (EOS) are reported. The gene discussed is GPT; the disease is liver disorder.